A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

NCT05343637 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

COMBINATION_PRODUCT: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

Sponsor

Respira Therapeutics, Inc.